Cybrexa has secured $25m to progress a cancer treatment based on research at Yale University and University of Rhode Island.
Cybrexa Therapeutics, a US-based oncology therapy developer exploiting Yale University and University of Rhode Island research, closed a $25m series B round yesterday featuring HighCape Capital and Elm Street Ventures.
Cybrexa is working on a platform that enables an antigen-independent targeting of tumours and intracellular delivery of cancer treatments.
The capital will allow Cybrexa to move its lead asset, CBX-12, into phase 1/2 trials in the first half of this year. The programme is aimed at advanced solid tumours.
Kevin…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
